[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feAznPtCaxl2ejq1GsiwB-1Nzkc8W71kCl3XE0MxXOko":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Methodist Health System",[4],167,false,38,2,4863460,1,150,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Trauma",7,{"name":18,"count":16},"COVID-19",{"name":20,"count":21},"Obesity",4,{"name":23,"count":21},"Liver Diseases",{"name":25,"count":26},"Cirrhosis",3,{"name":28,"count":26},"Gastro-Intestinal Disorder",{"name":30,"count":9},"Pancreas Cancer",{"name":32,"count":9},"Gastrointestinal Disease",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06096025","Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections","2026-06-23","pneumoniae bacteremia therapy",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,70,95,120,146,164,188,213,238,263,281,311,329,347,365,383,401,419,445,463,488,511,535,560,585,610],{"intervention":38,"totalTrials":11,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":60},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":51},[],{"trials":59,"activeCount":51},[],{"trials":61,"activeCount":11,"soonestReadout":37},[62],{"nctId":35,"briefTitle":36,"status":63,"phases":64,"primaryCompletion":37,"completion":37,"start":65,"enrollment":66,"conditions":67,"interventions":69},"ACTIVE_NOT_RECRUITING",[],"2023-06-23",200,[68],"Streptococcus Pneumoniae",[38],{"intervention":71,"totalTrials":11,"cells":72},"Fecal Microbiota Transplant",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":93},{"trials":74,"activeCount":51},[],{"trials":76,"activeCount":51},[],{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[83],{"nctId":84,"briefTitle":71,"status":85,"phases":86,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":92},"NCT04090346","COMPLETED",[44],"2022-03-30","2018-06-05",24,[91],"Clostridium Difficile Infection",[71],{"trials":94,"activeCount":51},[],{"intervention":96,"totalTrials":11,"cells":97},"Aromatherapy patches",{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":116,"NA":118},{"trials":99,"activeCount":51},[],{"trials":101,"activeCount":51},[],{"trials":103,"activeCount":51},[],{"trials":105,"activeCount":51},[106],{"nctId":107,"briefTitle":108,"status":85,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT05944120","Decreasing On-Shift Stress With a Crisis Intervention Cart",[43],"2024-01-31","2025-06-30","2023-03-06",443,[108],[96],{"trials":117,"activeCount":51},[],{"trials":119,"activeCount":51},[],{"intervention":121,"totalTrials":11,"cells":122},"Cephalosporin 1St Generation",{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":142,"NA":144},{"trials":124,"activeCount":51},[],{"trials":126,"activeCount":51},[],{"trials":128,"activeCount":51},[],{"trials":130,"activeCount":51},[131],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":51,"conditions":138,"interventions":140},"NCT05267977","Antibiotic Use & Open Fracture of the Lower Extremity","WITHDRAWN",[43],"2022-05-25","2016-08",[139],"Lower Extremity Fracture",[121,141],"Aminoglycosides",{"trials":143,"activeCount":51},[],{"trials":145,"activeCount":51},[],{"intervention":141,"totalTrials":11,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":160,"NA":162},{"trials":149,"activeCount":51},[],{"trials":151,"activeCount":51},[],{"trials":153,"activeCount":51},[],{"trials":155,"activeCount":51},[156],{"nctId":132,"briefTitle":133,"status":134,"phases":157,"primaryCompletion":136,"completion":136,"start":137,"enrollment":51,"conditions":158,"interventions":159},[43],[139],[121,141],{"trials":161,"activeCount":51},[],{"trials":163,"activeCount":51},[],{"intervention":165,"totalTrials":11,"cells":166},"Semaglutide",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":186},{"trials":168,"activeCount":51},[],{"trials":170,"activeCount":51},[171],{"nctId":172,"briefTitle":173,"status":134,"phases":174,"primaryCompletion":175,"completion":176,"start":175,"enrollment":51,"conditions":177,"interventions":179},"NCT06222437","Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy",[41],"2026-02","2027-02",[178],"Polycystic Ovary Syndrome",[165],{"trials":181,"activeCount":51},[],{"trials":183,"activeCount":51},[],{"trials":185,"activeCount":51},[],{"trials":187,"activeCount":51},[],{"intervention":189,"totalTrials":11,"cells":190},"Anti-MRSA therapy",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":201},{"trials":192,"activeCount":51},[],{"trials":194,"activeCount":51},[],{"trials":196,"activeCount":51},[],{"trials":198,"activeCount":51},[],{"trials":200,"activeCount":51},[],{"trials":202,"activeCount":51},[203],{"nctId":204,"briefTitle":205,"status":206,"phases":207,"primaryCompletion":208,"completion":208,"start":65,"enrollment":209,"conditions":210,"interventions":212},"NCT06096012","Don't Treat Ghosts Anti-MRSA Antibiotics in Osteomyelitis Without Identified MRSA","UNKNOWN",[],"2024-06-23",365,[211],"Osteomyelitis",[189],{"intervention":214,"totalTrials":11,"cells":215},"enoxaparin",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":217,"activeCount":51},[],{"trials":219,"activeCount":51},[],{"trials":221,"activeCount":51},[],{"trials":223,"activeCount":51},[],{"trials":225,"activeCount":51},[],{"trials":227,"activeCount":51},[228],{"nctId":229,"briefTitle":230,"status":206,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT06025162","Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma",[],"2024-08-31","2023-07-21",100,[236],"Thromboembolism, Venous",[214],{"intervention":239,"totalTrials":11,"cells":240},"Pfizer COVID-19 mRNA vaccine",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":242,"activeCount":51},[],{"trials":244,"activeCount":51},[],{"trials":246,"activeCount":51},[],{"trials":248,"activeCount":51},[],{"trials":250,"activeCount":51},[],{"trials":252,"activeCount":51},[253],{"nctId":254,"briefTitle":255,"status":85,"phases":256,"primaryCompletion":257,"completion":258,"start":257,"enrollment":234,"conditions":259,"interventions":261},"NCT05392075","COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose",[],"2023-03-15","2023-08-17",[260,18],"COVID-19 Pneumonia",[239,262],"Moderna COVID-19 mRNA vaccine",{"intervention":262,"totalTrials":11,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":266,"activeCount":51},[],{"trials":268,"activeCount":51},[],{"trials":270,"activeCount":51},[],{"trials":272,"activeCount":51},[],{"trials":274,"activeCount":51},[],{"trials":276,"activeCount":51},[277],{"nctId":254,"briefTitle":255,"status":85,"phases":278,"primaryCompletion":257,"completion":258,"start":257,"enrollment":234,"conditions":279,"interventions":280},[],[260,18],[239,262],{"intervention":282,"totalTrials":11,"cells":283},"Relistor Injectable Product",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":292,"NA":294},{"trials":285,"activeCount":51},[],{"trials":287,"activeCount":51},[],{"trials":289,"activeCount":51},[],{"trials":291,"activeCount":51},[],{"trials":293,"activeCount":51},[],{"trials":295,"activeCount":51},[296],{"nctId":297,"briefTitle":298,"status":134,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":302,"interventions":304},"NCT04930237","RELISTOR's Effects on Opioid-Induced Constipation",[],"2022-04-22","2021-07-01",[303],"OIC",[282,305,306,307,308,309,310],"Docusate Calcium","Bisacodyl","Milk of magnesia","Magnesium citrate","Senna","Enema",{"intervention":305,"totalTrials":11,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":323},{"trials":314,"activeCount":51},[],{"trials":316,"activeCount":51},[],{"trials":318,"activeCount":51},[],{"trials":320,"activeCount":51},[],{"trials":322,"activeCount":51},[],{"trials":324,"activeCount":51},[325],{"nctId":297,"briefTitle":298,"status":134,"phases":326,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":327,"interventions":328},[],[303],[282,305,306,307,308,309,310],{"intervention":306,"totalTrials":11,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":332,"activeCount":51},[],{"trials":334,"activeCount":51},[],{"trials":336,"activeCount":51},[],{"trials":338,"activeCount":51},[],{"trials":340,"activeCount":51},[],{"trials":342,"activeCount":51},[343],{"nctId":297,"briefTitle":298,"status":134,"phases":344,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":345,"interventions":346},[],[303],[282,305,306,307,308,309,310],{"intervention":307,"totalTrials":11,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":357,"NA":359},{"trials":350,"activeCount":51},[],{"trials":352,"activeCount":51},[],{"trials":354,"activeCount":51},[],{"trials":356,"activeCount":51},[],{"trials":358,"activeCount":51},[],{"trials":360,"activeCount":51},[361],{"nctId":297,"briefTitle":298,"status":134,"phases":362,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":363,"interventions":364},[],[303],[282,305,306,307,308,309,310],{"intervention":308,"totalTrials":11,"cells":366},{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":368,"activeCount":51},[],{"trials":370,"activeCount":51},[],{"trials":372,"activeCount":51},[],{"trials":374,"activeCount":51},[],{"trials":376,"activeCount":51},[],{"trials":378,"activeCount":51},[379],{"nctId":297,"briefTitle":298,"status":134,"phases":380,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":381,"interventions":382},[],[303],[282,305,306,307,308,309,310],{"intervention":309,"totalTrials":11,"cells":384},{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":386,"activeCount":51},[],{"trials":388,"activeCount":51},[],{"trials":390,"activeCount":51},[],{"trials":392,"activeCount":51},[],{"trials":394,"activeCount":51},[],{"trials":396,"activeCount":51},[397],{"nctId":297,"briefTitle":298,"status":134,"phases":398,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":399,"interventions":400},[],[303],[282,305,306,307,308,309,310],{"intervention":310,"totalTrials":11,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":404,"activeCount":51},[],{"trials":406,"activeCount":51},[],{"trials":408,"activeCount":51},[],{"trials":410,"activeCount":51},[],{"trials":412,"activeCount":51},[],{"trials":414,"activeCount":51},[415],{"nctId":297,"briefTitle":298,"status":134,"phases":416,"primaryCompletion":300,"completion":300,"start":301,"enrollment":51,"conditions":417,"interventions":418},[],[303],[282,305,306,307,308,309,310],{"intervention":420,"totalTrials":11,"cells":421},"IV antibiotic treatment from prior",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":432},{"trials":423,"activeCount":51},[],{"trials":425,"activeCount":51},[],{"trials":427,"activeCount":51},[],{"trials":429,"activeCount":51},[],{"trials":431,"activeCount":51},[],{"trials":433,"activeCount":51},[434],{"nctId":435,"briefTitle":436,"status":85,"phases":437,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":443},"NCT05171257","Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit",[],"2025-07-14","2021-10-19",197,[442],"Gram-Negative Bacterial Infections",[420,444],"differing IV antibiotic treatment",{"intervention":444,"totalTrials":11,"cells":446},{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":448,"activeCount":51},[],{"trials":450,"activeCount":51},[],{"trials":452,"activeCount":51},[],{"trials":454,"activeCount":51},[],{"trials":456,"activeCount":51},[],{"trials":458,"activeCount":51},[459],{"nctId":435,"briefTitle":436,"status":85,"phases":460,"primaryCompletion":438,"completion":438,"start":439,"enrollment":440,"conditions":461,"interventions":462},[],[442],[420,444],{"intervention":464,"totalTrials":11,"cells":465},"doxycycline",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":467,"activeCount":51},[],{"trials":469,"activeCount":51},[],{"trials":471,"activeCount":51},[],{"trials":473,"activeCount":51},[],{"trials":475,"activeCount":51},[],{"trials":477,"activeCount":51},[478],{"nctId":479,"briefTitle":480,"status":85,"phases":481,"primaryCompletion":482,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":487},"NCT04153604","Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis",[],"2020-08-07","2019-11-04",841,[25,486],"Spontaneous Bacterial Peritonitis",[464],{"intervention":489,"totalTrials":11,"cells":490},"antimetabolite",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":501},{"trials":492,"activeCount":51},[],{"trials":494,"activeCount":51},[],{"trials":496,"activeCount":51},[],{"trials":498,"activeCount":51},[],{"trials":500,"activeCount":51},[],{"trials":502,"activeCount":51},[503],{"nctId":504,"briefTitle":505,"status":85,"phases":506,"primaryCompletion":507,"completion":507,"start":439,"enrollment":234,"conditions":508,"interventions":510},"NCT05238155","Evaluation of the Impact of Reduced Immunosuppression",[],"2025-07-29",[509],"Graft Vs Host Disease",[489],{"intervention":512,"totalTrials":11,"cells":513},"Antibiotic",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":515,"activeCount":51},[],{"trials":517,"activeCount":51},[],{"trials":519,"activeCount":51},[],{"trials":521,"activeCount":51},[],{"trials":523,"activeCount":51},[],{"trials":525,"activeCount":51},[526],{"nctId":527,"briefTitle":528,"status":85,"phases":529,"primaryCompletion":438,"completion":438,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT06112938","Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia",[],"2022-07-21",110,[533],"Stenotrophomonas Maltophilia Infection",[512],{"intervention":536,"totalTrials":11,"cells":537},"PSMA radionuclide therapy",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":539,"activeCount":51},[],{"trials":541,"activeCount":51},[],{"trials":543,"activeCount":51},[],{"trials":545,"activeCount":51},[],{"trials":547,"activeCount":51},[],{"trials":549,"activeCount":51},[550],{"nctId":551,"briefTitle":552,"status":206,"phases":553,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT05995236","Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy",[],"2024-08-02","2023-08-02",400,[558],"Prostate Cancer",[536],{"intervention":561,"totalTrials":11,"cells":562},"Antibiotics",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":564,"activeCount":51},[],{"trials":566,"activeCount":51},[],{"trials":568,"activeCount":51},[],{"trials":570,"activeCount":51},[],{"trials":572,"activeCount":51},[],{"trials":574,"activeCount":51},[575],{"nctId":576,"briefTitle":577,"status":206,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":584},"NCT04925531","Antibiotic Use in Facial Fracture Post Injury",[],"2024-07-23","2016-07-29",1000,[583],"Trauma Injury",[561],{"intervention":586,"totalTrials":11,"cells":587},"sacubitril\u002Fvalsartan",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":589,"activeCount":51},[],{"trials":591,"activeCount":51},[],{"trials":593,"activeCount":51},[],{"trials":595,"activeCount":51},[],{"trials":597,"activeCount":51},[],{"trials":599,"activeCount":51},[600],{"nctId":601,"briefTitle":602,"status":85,"phases":603,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":609},"NCT05168787","Efficacy and Safety of Sacubitril\u002FValsartan in African American Patients With Heart Failure With Reduced Ejection Fraction",[],"2025-07-08","2020-08-13",6558,[608],"Heart Failure",[586],{"intervention":611,"totalTrials":11,"cells":612},"Omadacycline",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":614,"activeCount":51},[],{"trials":616,"activeCount":51},[],{"trials":618,"activeCount":51},[],{"trials":620,"activeCount":51},[],{"trials":622,"activeCount":51},[],{"trials":624,"activeCount":51},[625],{"nctId":626,"briefTitle":627,"status":85,"phases":628,"primaryCompletion":438,"completion":438,"start":629,"enrollment":630,"conditions":631,"interventions":633},"NCT04714411","Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis",[],"2020-11-05",42,[632],"Diabetic Foot Infection",[611]]